Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 36 entries
Sorted by: Best Match Show Resources per page
Local Drug Delivery During Percutaneous Coronary Intervention.

Current interventional cardiology reports

Bailey S.
PMID: 11096686
Curr Interv Cardiol Rep. 2000 Nov;2(4):349-357.

Local delivery of therapeutic agents offers promise as adjuncts during percutaneous interventions. The potential advantages of local delivery include direct delivery to the lesion site, lower doses of the agent resulting in lower costs and/or greater efficiency, and the...

Cite
Bailey S. Local Drug Delivery During Percutaneous Coronary Intervention. Curr Interv Cardiol Rep. 2000;2(4):349-357
Bailey, S. (2000). Local Drug Delivery During Percutaneous Coronary Intervention. Current interventional cardiology reports, 2(4), 349-357.
Bailey. "Local Drug Delivery During Percutaneous Coronary Intervention." Current interventional cardiology reports vol. 2,4 (2000): 349-357.
Bailey S. Local Drug Delivery During Percutaneous Coronary Intervention. Curr Interv Cardiol Rep. 2000 Nov;2(4):349-357. PMID: 11096686.
Copy Download .nbib Format: NLM
Cervicocranial arterial dissection.

Current treatment options in neurology

Shah Q, Messé SR.
PMID: 17288890
Curr Treat Options Neurol. 2007 Jan;9(1):55-62. doi: 10.1007/s11940-007-0031-4.

Cervicocranial arterial dissection (CCAD) occurs when there is a tear in the intimal layer of the carotid or vertebral arteries with subsequent extravasation of blood into the subintimal layers. The dissection may be extradural, intradural, or extend over both...

Cite
Shah Q, Messé SR. Cervicocranial arterial dissection. Curr Treat Options Neurol. 2007;9(1):55-62doi: 10.1007/s11940-007-0031-4.
Shah, Q., & Messé, S. R. (2007). Cervicocranial arterial dissection. Current treatment options in neurology, 9(1), 55-62. https://doi.org/10.1007/s11940-007-0031-4
Shah, Qaisar, and Messé, Steven R. "Cervicocranial arterial dissection." Current treatment options in neurology vol. 9,1 (2007): 55-62. doi: https://doi.org/10.1007/s11940-007-0031-4
Shah Q, Messé SR. Cervicocranial arterial dissection. Curr Treat Options Neurol. 2007 Jan;9(1):55-62. doi: 10.1007/s11940-007-0031-4. PMID: 17288890.
Copy Download .nbib Format: NLM
The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?.

Research and practice in thrombosis and haemostasis

De Kesel PMM, Devreese KMJ.
PMID: 31989098
Res Pract Thromb Haemost. 2019 Dec 10;4(1):161-168. doi: 10.1002/rth2.12264. eCollection 2020 Jan.

BACKGROUND: Heparins and heparinoids interfere with functional clotting assays used for lupus anticoagulant (LAC) detection. However, current guidelines for LAC testing do not provide clear guidance on this matter.OBJECTIVES: We aimed to assess to effect of unfractionated heparin (UFH),...

Cite
De Kesel PMM, Devreese KMJ. The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?. Res Pract Thromb Haemost. 2019;4(1):161-168doi: 10.1002/rth2.12264.
De Kesel, P. M. M., & Devreese, K. M. J. (2020). The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?. Research and practice in thrombosis and haemostasis, 4(1), 161-168. https://doi.org/10.1002/rth2.12264
De Kesel, Pieter M M, and Devreese, Katrien M J. "The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?." Research and practice in thrombosis and haemostasis vol. 4,1 (2020): 161-168. doi: https://doi.org/10.1002/rth2.12264
De Kesel PMM, Devreese KMJ. The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?. Res Pract Thromb Haemost. 2019 Dec 10;4(1):161-168. doi: 10.1002/rth2.12264. eCollection 2020 Jan. PMID: 31989098; PMCID: PMC6971310.
Copy Download .nbib Format: NLM
A Case of Livedoid Vasculopathy Successfully Treated with Sulodexide.

Annals of dermatology

Song CH, Shin DS, Jang JW, Kim TL, Kim YG, Kim JS, Seo HM.
PMID: 33911794
Ann Dermatol. 2020 Dec;32(6):508-511. doi: 10.5021/ad.2020.32.6.508. Epub 2020 Nov 11.

We report a 29-year-old female with a one-month history of non-healing multiple erythematous to violaceous plaques with crusts over both legs and feet. Tender, scarring ulcers with surrounding erythema were present. The clinical manifestation, together with histopathologic findings of...

Cite
Song CH, Shin DS, Jang JW, et al. A Case of Livedoid Vasculopathy Successfully Treated with Sulodexide. Ann Dermatol. 2020;32(6):508-511doi: 10.5021/ad.2020.32.6.508.
Song, C. H., Shin, D. S., Jang, J. W., Kim, T. L., Kim, Y. G., Kim, J. S., & Seo, H. M. (2020). A Case of Livedoid Vasculopathy Successfully Treated with Sulodexide. Annals of dermatology, 32(6), 508-511. https://doi.org/10.5021/ad.2020.32.6.508
Song, Chang Hwa, et al. "A Case of Livedoid Vasculopathy Successfully Treated with Sulodexide." Annals of dermatology vol. 32,6 (2020): 508-511. doi: https://doi.org/10.5021/ad.2020.32.6.508
Song CH, Shin DS, Jang JW, Kim TL, Kim YG, Kim JS, Seo HM. A Case of Livedoid Vasculopathy Successfully Treated with Sulodexide. Ann Dermatol. 2020 Dec;32(6):508-511. doi: 10.5021/ad.2020.32.6.508. Epub 2020 Nov 11. PMID: 33911794; PMCID: PMC7875231.
Copy Download .nbib Format: NLM
New Therapeutic Opportunities for Heparins: What Does Low Molecular Weight Heparin Offer?.

Journal of thrombosis and thrombolysis

Turpie AG.
PMID: 10602555
J Thromb Thrombolysis. 1996;3(2):145-149. doi: 10.1007/BF00132407.

New advances in antithrombotic therapy include direct thrombin inhibitors and low molecular weight heparins and heparinoids. Low molecular weight heparins and heparinoids have improved pharmacologic and pharmacokinetic properties when compared with unfractionated heparin. Low-molecular weight heparins are effective in...

Cite
Turpie AG. New Therapeutic Opportunities for Heparins: What Does Low Molecular Weight Heparin Offer?. J Thromb Thrombolysis. 1996;3(2):145-149doi: 10.1007/BF00132407.
Turpie, A. G. (1996). New Therapeutic Opportunities for Heparins: What Does Low Molecular Weight Heparin Offer?. Journal of thrombosis and thrombolysis, 3(2), 145-149. https://doi.org/10.1007/BF00132407
Turpie. "New Therapeutic Opportunities for Heparins: What Does Low Molecular Weight Heparin Offer?." Journal of thrombosis and thrombolysis vol. 3,2 (1996): 145-149. doi: https://doi.org/10.1007/BF00132407
Turpie AG. New Therapeutic Opportunities for Heparins: What Does Low Molecular Weight Heparin Offer?. J Thromb Thrombolysis. 1996;3(2):145-149. doi: 10.1007/BF00132407. PMID: 10602555.
Copy Download .nbib Format: NLM
Delayed-type heparin allergy: diagnostic procedures and treatment alternatives-a case series including 15 patients.

The World Allergy Organization journal

Pföhler C, Müller CS, Pindur G, Eichler H, Schäfers HJ, Grundmann U, Tilgen W.
PMID: 23282847
World Allergy Organ J. 2008 Dec;1(12):194-9. doi: 10.1097/WOX.0b013e31818def58.

Delayed-type hypersensitivity reactions (DTHRs) after subcutaneous application of unfractionated heparins or low-molecular-weight heparins are not uncommon. Standard allergological testing usually includes intracutaneous skin tests and patch testing of different heparins, heparinoids, and thrombin inhibitors followed by subcutaneous and/or intravenous...

Cite
Pföhler C, Müller CS, Pindur G, et al. Delayed-type heparin allergy: diagnostic procedures and treatment alternatives-a case series including 15 patients. World Allergy Organ J. 2008;1(12):194-9doi: 10.1097/WOX.0b013e31818def58.
Pföhler, C., Müller, C. S., Pindur, G., Eichler, H., Schäfers, H. J., Grundmann, U., & Tilgen, W. (2008). Delayed-type heparin allergy: diagnostic procedures and treatment alternatives-a case series including 15 patients. The World Allergy Organization journal, 1(12), 194-9. https://doi.org/10.1097/WOX.0b013e31818def58
Pföhler, Claudia, et al. "Delayed-type heparin allergy: diagnostic procedures and treatment alternatives-a case series including 15 patients." The World Allergy Organization journal vol. 1,12 (2008): 194-9. doi: https://doi.org/10.1097/WOX.0b013e31818def58
Pföhler C, Müller CS, Pindur G, Eichler H, Schäfers HJ, Grundmann U, Tilgen W. Delayed-type heparin allergy: diagnostic procedures and treatment alternatives-a case series including 15 patients. World Allergy Organ J. 2008 Dec;1(12):194-9. doi: 10.1097/WOX.0b013e31818def58. PMID: 23282847; PMCID: PMC3650972.
Copy Download .nbib Format: NLM
Size matters.

Blood

Gruber A, Tucker EI.
PMID: 22174307
Blood. 2011 Dec 15;118(25):6481-2. doi: 10.1182/blood-2011-10-382622.

In this issue of Blood, Yau and colleagues provide evidence that guide catheter thrombosis in patients undergoing percutaneous coronary intervention (PCI) is initiated by contact system activation, and that unfractionated heparin is more effective than fondaparinux at limiting catheter...

Cite
Gruber A, Tucker EI. Size matters. Blood. 2011;118(25):6481-2doi: 10.1182/blood-2011-10-382622.
Gruber, A., & Tucker, E. I. (2011). Size matters. Blood, 118(25), 6481-2. https://doi.org/10.1182/blood-2011-10-382622
Gruber, Andras, and Tucker, Erik I. "Size matters." Blood vol. 118,25 (2011): 6481-2. doi: https://doi.org/10.1182/blood-2011-10-382622
Gruber A, Tucker EI. Size matters. Blood. 2011 Dec 15;118(25):6481-2. doi: 10.1182/blood-2011-10-382622. PMID: 22174307.
Copy Download .nbib Format: NLM
Treatment of acute ischemic stroke.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

Alberts MJ.
PMID: 17903844
J Stroke Cerebrovasc Dis. 2001 Mar-Apr;10(2):10-7. doi: 10.1053/jscd.2001.24778.

Acute ischemic stroke remains difficult to treat despite the advent of new therapies. The only approved medication to reverse its effects is recombinant tissue plasminogen activator administered intravenously within 3 hours of onset of stroke symptoms--an opportunity that does...

Cite
Alberts MJ. Treatment of acute ischemic stroke. J Stroke Cerebrovasc Dis. 2001;10(2):10-7doi: 10.1053/jscd.2001.24778.
Alberts, M. J. (2001). Treatment of acute ischemic stroke. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 10(2), 10-7. https://doi.org/10.1053/jscd.2001.24778
Alberts, M J. "Treatment of acute ischemic stroke." Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association vol. 10,2 (2001): 10-7. doi: https://doi.org/10.1053/jscd.2001.24778
Alberts MJ. Treatment of acute ischemic stroke. J Stroke Cerebrovasc Dis. 2001 Mar-Apr;10(2):10-7. doi: 10.1053/jscd.2001.24778. PMID: 17903844.
Copy Download .nbib Format: NLM
Identification and treatment of arterial thrombophilia.

Current treatment options in cardiovascular medicine

Chan MY, Becker RC.
PMID: 18325302
Curr Treat Options Cardiovasc Med. 2008 Feb;10(1):3-11. doi: 10.1007/s11936-008-0001-5.

Once the diagnosis of a thrombophilic state has been established, management must include one or more strategies designed to attenuate thrombotic risk and the likelihood of clinical events. In the case of drug-induced arterial thrombosis provoked by oral contraceptives,...

Cite
Chan MY, Becker RC. Identification and treatment of arterial thrombophilia. Curr Treat Options Cardiovasc Med. 2008;10(1):3-11doi: 10.1007/s11936-008-0001-5.
Chan, M. Y., & Becker, R. C. (2008). Identification and treatment of arterial thrombophilia. Current treatment options in cardiovascular medicine, 10(1), 3-11. https://doi.org/10.1007/s11936-008-0001-5
Chan, Mark Y, and Becker, Richard C. "Identification and treatment of arterial thrombophilia." Current treatment options in cardiovascular medicine vol. 10,1 (2008): 3-11. doi: https://doi.org/10.1007/s11936-008-0001-5
Chan MY, Becker RC. Identification and treatment of arterial thrombophilia. Curr Treat Options Cardiovasc Med. 2008 Feb;10(1):3-11. doi: 10.1007/s11936-008-0001-5. PMID: 18325302.
Copy Download .nbib Format: NLM
Oral heparin (Emisphere).

IDrugs : the investigational drugs journal

Dunn A.
PMID: 16080057
IDrugs. 2000 Jul;3(7):817-24.

Emisphere (formerly in collaboration with Elan) is developing an oral heparin formulation for the potential treatment of deep vein thrombosis (DVT). The formulation uses Emisphere's proprietary carrier molecule, P-414, and had started phase III trials by January 2000 [353372]....

Cite
Dunn A. Oral heparin (Emisphere). IDrugs. 2000;3(7):817-24
Dunn, A. (2000). Oral heparin (Emisphere). IDrugs : the investigational drugs journal, 3(7), 817-24.
Dunn, A. "Oral heparin (Emisphere)." IDrugs : the investigational drugs journal vol. 3,7 (2000): 817-24.
Dunn A. Oral heparin (Emisphere). IDrugs. 2000 Jul;3(7):817-24. PMID: 16080057.
Copy Download .nbib Format: NLM
Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Lubenow N, Greinacher A.
PMID: 18034563
BioDrugs. 2000 Aug;14(2):109-25. doi: 10.2165/00063030-200014020-00005.

Recombinant hirudins have a definite role in the treatment of patients with heparin-induced thrombocytopenia (HIT). The most important adverse effects are haemorrhages and the induction of antihirudin antibodies. Major haemorrhages were not significantly increased in patients with HIT compared...

Cite
Lubenow N, Greinacher A. Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin. BioDrugs. 2000;14(2):109-25doi: 10.2165/00063030-200014020-00005.
Lubenow, N., & Greinacher, A. (2000). Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 14(2), 109-25. https://doi.org/10.2165/00063030-200014020-00005
Lubenow, N, and Greinacher, A. "Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 14,2 (2000): 109-25. doi: https://doi.org/10.2165/00063030-200014020-00005
Lubenow N, Greinacher A. Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin. BioDrugs. 2000 Aug;14(2):109-25. doi: 10.2165/00063030-200014020-00005. PMID: 18034563.
Copy Download .nbib Format: NLM
SARS-CoV-2 and pulmonary embolism: who stole the platelets?.

Thrombosis journal

Tran M, Sheth C, Bhandari R, Cameron SJ, Hornacek D.
PMID: 32905282
Thromb J. 2020 Sep 03;18:16. doi: 10.1186/s12959-020-00229-8. eCollection 2020.

BACKGROUND: Patients infected with SARS-CoV-2 often develop venous and arterial thrombosis. The high patient mortality is partly attributed to thrombotic events. An emerging trend is the presence of immunological phenomena including antiphospholipid antibodies which may promote thrombosis. The mechanism...

Cite
Tran M, Sheth C, Bhandari R, et al. SARS-CoV-2 and pulmonary embolism: who stole the platelets?. Thromb J. 2020;18:16doi: 10.1186/s12959-020-00229-8.
Tran, M., Sheth, C., Bhandari, R., Cameron, S. J., & Hornacek, D. (2020). SARS-CoV-2 and pulmonary embolism: who stole the platelets?. Thrombosis journal, 1816. https://doi.org/10.1186/s12959-020-00229-8
Tran, Michael, et al. "SARS-CoV-2 and pulmonary embolism: who stole the platelets?." Thrombosis journal vol. 18 (2020): 16. doi: https://doi.org/10.1186/s12959-020-00229-8
Tran M, Sheth C, Bhandari R, Cameron SJ, Hornacek D. SARS-CoV-2 and pulmonary embolism: who stole the platelets?. Thromb J. 2020 Sep 03;18:16. doi: 10.1186/s12959-020-00229-8. eCollection 2020. PMID: 32905282; PMCID: PMC7467753.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 36 entries